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512Objectives: Surgical treatment of aortic valve (AoV) disease in childhood involves complex decisions partic-
ularly in very small patients. There is no consensus regarding the optimum surgical option. The objective of this
review was to analyze a contemporary experience of AoV surgery in a large children’s hospital.
Methods: A retrospective review of children (aged 18 years) undergoing AoV repair or replacement from
June 1995 to December 2011 was carried out.
Results:A total of 285 AoVoperations (97 repairs, 188 replacements) were performed on 241 patients. Hospital
survival for repair was 98% and for replacements was 97%. At follow-up of repairs, there were 16 (17%)
reoperations and 3 (3%) late deaths. Follow-up of AoV replacements demonstrated 31 (16%) reoperations
(homograft 27, autograft 3, mechanical 1) and 8 (4%) late deaths (homograft 5, autograft 2, mechanical 1).
Freedom from reintervention or death (FRD) was found to be lower in repairs for infants (P¼ .048) and truncal
valves (P< .05). For AoV replacements, infants and patients who had concomitant CHD or homografts
(P<.0001) had lower FRD. Cox regression analysis for AoV replacements identified infants and homograft
root replacements at a higher risk for death/reoperation.
Conclusions: AoV repairs and replacements were generally found to be associated with low death and
reoperation rates at long-term follow-up. Infants had a lower freedom from reintervention or death after either
an AoV repair or replacement, although truncal valve repairs and AoV replacement in patients with concomitant
CHD were associated with lower valve survival. Among the valve options, homograft root replacement had
a higher risk of death/reoperation and lowest freedom from reintervention or death. (J Thorac Cardiovasc
Surg 2013;146:512-21)Surgical treatment of aortic valve (AoV) disease in children
involves complex decisions with the prospect of impact on
decades of life. Although a variety of treatment strategies
exist, essentially no option can be construed as a definitively
durable long-term solution if one considers the potential of
a normal lifespan. In most children undergoing surgery for
AoV disease, reoperation is an unavoidable outcome.
Currently there is no consensus on the best treatment for
AoV disease in the pediatric patient.
There appears to be a wide variation in practice patterns
relative to treatment of AoV disease in children.1,2 This
observation is logically associated with the lack of a truly
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The Journal of Thoracic and Cardiovascular Surgideal pediatric valve substitute offers indefinite dura-
bility, does not elicit a host immune response, offers
a hemodynamic profile comparable with that of a normal
native AoV, does not require anticoagulation, is easy and
safe to implant, and perhaps most important, has the
potential for appropriate somatic growth in synchrony
with the patient. Given the widely perceived lack of
a perfect valve replacement option in childhood, most
pediatric cardiac surgeons believe native AoV repair is
a viable palliative option for appropriate patients.3-5
Although AoV repair is safe and in many series reported
to offer acceptable intermediate term valve function,
reoperation remains a certainty.6,7
The surgeon who counsels a family about AoV replace-
ment options faces the daunting task of attempting to assimi-
late incomplete data from relatively small series if one
considers the aggregate pediatric experience in comparison
with that in adult cardiac surgery. Options include the broad
categories of mechanical prostheses, human cadaveric re-
placement (homograft root), pulmonary autograft root (Ross
procedure), and various bioprostheses. This may present
a confusing and even frustrating conundrum for the family.
Although definite institutional biases exist, there are limited
objective long-term data available to aid in this process.
At our own institution, we have observed a wide variety
of treatment options being offered to children with AoVery c September 2013
Abbreviations and Acronyms
ACEi/
ARBS
¼ angiotensin-converting enzyme
inhibitor/angiotensin receptor blocker
AoV ¼ aortic valve
CHD ¼ congenital heart disease
FRD ¼ freedom from reintervention or death
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the contemporary outcomes of children undergoing AoV
surgery in a large children’s hospital.
METHODS
This was a retrospective review of patients who have undergone repair
or a replacement of the AoVat Texas Children’s Hospital from June 1995 to
December 2011. Patients who were aged 18 years at surgery were in-
cluded. Institutional review board approval from the Baylor College of
Medicine was obtained for conducting this study.
Data Collection
Data were collected on study participants from electronic databases
(Congenital Heart Surgery database, Pediatric Cardiology/Echo databases)
and clinical records. To provide the most complete follow-up, we directly
contacted families of patients not recently seen at our institution and con-
ducted telephone interviews. Long-term subject follow-up (after hospital
discharge) was 85% complete for this cohort. Accepted guidelines for re-
porting morbidity and mortality after cardiac valve interventions were
used.8
The entire cohort was divided into 2 primary study groups: AoV repair
or replacement.
AoV repair. Subjects who underwent repair were subclassified into 3
clinical categories: isolated AoV disease, AoV disease associated with sig-
nificant other congenital heart disease (CHD), and truncus arteriosus with
valve dysfunction. Repairs were additionally analyzed on the basis of the
surgical procedure performed and classified as simple or complex. Com-
plex repairs included leaflet resuspension, elevation, augmentation, exten-
sive leaflet debridement requiring reconstruction, resection and
subcommissural leaflet plication, annuloplasty, valve-sparing root repair,
and Trusler repair. All other repairs were classified as simple. Any repair
associated with concomitant subaortic membrane resection was excluded
from the cohort.
AoV replacement. Subjects undergoing AoV replacement were also
subclassified according to choice of valve substitute. Groups included pa-
tients undergoing pulmonary autograft root replacement (Ross procedure),
homograft root replacement, mechanical/composite valve (as isolated
valve or Bentall procedure), and bioprosthetic valves. Patients undergoing
concomitant root-enlarging procedures were included.
Variables
Variables analyzed include gender, age, and weight at surgery, number
of previous AoVoperations, number of previous interventional aortic val-
vuloplasties, diagnostic criteria (described earlier), valve repair type, type
of valve replacement, time receiving ventilatory support, duration of stay in
the intensive care unit and hospital, postoperative complications, and dis-
charge status. Preoperative and last follow-up echocardiographic measure-
ments of severity of valve dysfunction, left ventricular end-diastolic and
end-systolic dimensions, Z-scores (number of standard deviations above
or below mean expected dimension for body surface area), shortening frac-
tion Z-scores as a measure of left ventricular function, reoperations, and
mortality were also reported.The Journal of Thoracic and CaDATA ANALYSIS
Continuous variables were reported as median with min-
imums and maximums or means with standard deviations.
Frequencies were calculated for categorical variables with
percentages. Replacement and repair failures and mortality
were modeled as time-dependent events using the Kaplan-
Meier and life table methods and reported as freedom from
reintervention on the AoVor death (FRD). Any reinterven-
tion other than the AoV, for example, the right-sided rein-
terventions after a Ross procedure, were not a part of this
analysis. Factors associated with treatment failures were
analyzed using the multivariable Cox regression models
separately for AoV repairs and replacements. All data
were analyzed using IBM SPSS version 19 (IBM, Armonk,
NY).RESULTS
A total of 241 children underwent 285 AoV operations
during the study period. The median age at first operation
was 6.8 years (1 day-18 years) and 87 (36%) patients
were female. The median weight at first operation was
21.7 kg (2-110.2 kg).AoV Repairs
Ninety-two patients (36 [39%] female) underwent 97
AoV repairs at a median age and weight of 2.6 years
(1-18 years) and 11.6 kg (2.1-110.2 kg), respectively. The
majority (74, 76%) of patients undergoing AoV repairs
had concomitant CHD (including 22 [23%] patients with
truncal valve insufficiency) and 23 (23%) patients had iso-
lated AoV disease. The majority (80, 82%) of patients who
underwent AoV repair had no prior AoV intervention (cath-
eter or surgical). Forty-one (42%) patients underwent sim-
ple AoV repair and 56 (58%) had complex AoV repair
(Table 1). Indications for AoV repair included insufficiency
in 46 (47%), stenosis in 17 (18%), and combined insuffi-
ciency and stenosis in 31 (32%), whereas 3 (3%) patients
had dilation of the aortic root with no valve dysfunction.
In total, 8 (8%) patients had aortic root dilation requiring
valve-sparing root repair. (For echocardiographic severity
of valve dysfunction, refer to Table 2.)Postoperative Course
Postoperative complications were infrequent in patients
undergoing AoV repair and included bleeding requiring
postoperative transfusion or surgical exploration in 4 (4%)
patients, nosocomial infections in 8 (8%) patients, renal
insufficiency in 3 (3%) patients, chylothorax in 1 (1%) pa-
tient, and heart and respiratory failure postoperatively sec-
ondary to multiple complex defects and repairs in 1 (1%)
patient. Two patients had immediate failure of repair (within
24 hours) requiring AoV replacement owing to stenosis (1)
or insufficiency (1). There were 2 hospital deaths: 1 patientrdiovascular Surgery c Volume 146, Number 3 513
TABLE 1. Characteristics of pediatric patients that underwent AoV repair
Characteristics Simple repair (n ¼ 41) Complex repair (n ¼ 56) P value
Median age (range) 7.5 mo (1 d-16.8 y) 4.3 y (5 d-18 y) .037
Female (%) 15 (37) 24 (43) .675
Median weight (kg, range) 6.8 (2.4-93) 20.1 (2.1-110.2) .033
Diagnostic groups
AoV disease only (%) 11 (27) 12 (22) <.0001
AoV disease with other CHD (%) 30 (73) 22 (39)
Truncal valve (%) 0 (0) 22 (39)
Previous BAV (%) 6 (15) 3 (5) .161
Previous AoV interventions (%) 7 (17) 11 (20) .797
Mean CPB time  SD (min) 166  52 215  79 .001
Mean crossclamp time  SD (min) 104  41 137  62 .005
Median ventilator time (d, range) 1 (0-10) 1 (0-14) .658
Median ICU length of stay (d, range) 4 (1-12) 3 (0-9) .027
Median hospital length of stay (d, range) 8 (3-194) 6 (1-141) .094
Thirty-day survival (%) 40 (98) 55 (98) 1.0
P values in bold are significant. AoV, Aortic valve; CHD, congenital heart disease; BAV, aortic valvuloplasty; CPB, cardiopulmonary bypass; SD, standard deviation; ICU, in-
tensive care unit.
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modynamic instability after repair and 1 infant with severe
aortic stenosis and mitral valve stenosis/insufficiency with
discontinuous pulmonary arteries died after a prolonged
hospital course involvingmultiple reoperations for recurrent
aortic stenosis. The patient required a left ventricular assist
device, had pulmonary hypertension, and had a number of
infections leading to death. Hospital survival after AoV re-
pair was 98% (Table 3).
Late Complications
At a mean follow-up time of 3.7 3.8 years (8 days-15.4
years); there were 16 (17%) reoperations and 3 late deaths.
Complications at long-term follow-up for the 76 surviving
patients without further AoV intervention included sub-
acute bacterial endocarditis in 1 (1%), supraventricular
tachycardia in 1 (1%), hypertensive cardiomyopathy in 1
(1%), recurrence of insufficiency in 38 (50%), stenosis inTABLE 2. Preoperative and follow-up AoV dysfunction in repairs and rep
Echocardiographic findings
AoV repairs
Preoperative (n ¼ 97) Follow-up
Stenosisy
Severe 12 (12%) —
Moderate 14 (14%) 6 (9
Mild 21 (22%) 26 (4
Trivial 1 (1%) —
Insufficiencyy
Severe 18 (19%) 2 (3
Moderate 32 (33%) 14 (2
Mild 20 (21%) 27 (4
Trivial 7 (7%) 14 (2
Mean LVEDD  SD 1.50  2.7 0.48
Mean LVESD  SD 0.69  2.8 0.04 
Mean SF  SD 0.46  2.7 0.51 
AoV, Aortic valve; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricul
patients alive without further reintervention. yIncludes combined insufficiency and stenos
514 The Journal of Thoracic and Cardiovascular Surg14 (18%), and combined insufficiency and stenosis in 18
(24%). For severity of valve dysfunction based on echocar-
diographic, data refer to Table 2.Risk Factors for Repair Failure and FRD
Factors significantly associated with repair failure (reop-
eration or death) on univariate analysis were infant age
group (P ¼ .05), complex repair type (P ¼ .05), and the di-
agnosis of truncus arteriosus (P ¼ .001). However, multi-
variable Cox regression analysis showed no significant
difference among these risk factors. On Kaplan-Meier anal-
ysis, infants (P ¼ .048) and truncal valves were found to
have the lowest FRD (P<.05) (Figure 1, A-C).AoV Replacement
One hundred sixty-two children (57 [35.2%] female)
underwent 188 valve replacements at a median age oflacements
AoV replacements
* (n ¼ 64) Preoperative (n ¼ 188) Follow-up* (n ¼ 143)
27 (14%) 5 (3%)
%) 41 (22%) 9 (6%)
1%) 41 (22%) 15 (10%)
— 8 (6%)
%) 58 (31%) 10 (7%)
2%) 52 (28%) 15 (10%)
2%) 29 (15%) 55 (38%)
2%) 8 (4%) 65 (45%)
 1.9 1.94  2.9 0.32  1.6
1.73 2.61  1.0 0.63  1.9
1.68 0.92  3.1 0.56  2.4
ar end-systolic dimension; SF, shortening fraction; SD, standard deviation. *Includes
is.
ery c September 2013
TABLE 3. Characteristics of pediatric patients that underwent AoV replacement
Characteristics Autograft (n ¼ 68) Homograft (n ¼ 74) Mechanical (n ¼ 36) Bioprosthetic (n ¼ 10) P value*
Median age (range) 5.9 y (6 d-17 y) 4.9 y (4 d-16.5 y) 14 y (2.1-17.8 y) 15.9 y (5.5-18 y) <.0001
Females (%) 21 (31) 27 (37) 15 (42) 3 (30) .594
Median weight (kg, range) 21.0 (3.4-96) 17.8 (2-96.3) 48.9 (10-109.3) 63.0 (20-89.1) <.0001
Diagnostic groups
AoV disease only (%) 47 (69) 26 (35) 12 (33) 10 (100) .168
AoV disease with other CHD (%) 21 (31) 41 (55) 18 (50) —
Truncal valve (%) — 7 (10) 6 (17) —
Previous BAV (%) 29 (43) 20 (27) 6 (17) 3 (30) .067
Previous AoV interventions (%) 45 (66) 29 (39) 19 (53) 5 (50) 1.0
Mean valve size (mm, range) — 15 (7-26) 22 (17-29) 22 (19-27) <.0001
Mean CPB time  SD (min) 288  75 262  69 229  77 238  87 .001
Mean crossclamp time  SD (min) 191  40 189  44 163  54 174  65 .002
Mean ventilator time (d, range) 1 (0-67) 1 (0-35) 1 (0-8) 0 (0-1) .01
Median ICU length of stay (d, range) 3 (1-67) 3 (0-35) 3 (1-23) 2 (1-7) .336
Median hospital length of stay (d, range) 6 (3-98) 6 (0-58) 7 (4-29) 7 (3-12) .066
Thirty-day survival (%) 67 (99) 71 (96) 36 (100) 10 (100) .44
P values in bold are significant. AoV, Aortic valve; CHD, congenital heart disease; BAV, aortic valvuloplasty; CPB, cardiopulmonary bypass; SD, standard deviation; ICU, in-
tensive care unit. *Comparison between valves for younger children (autograft and homografts) versus older children (mechanical and bioprosthetic).
Khan et al Congenital Heart Disease
C
H
D8.3 years (4 days-18 years) and median weight of 25.4 kg
(2-109.3 kg). Indications for replacements included com-
bined AoV insufficiency and stenosis in 93 (49%), insuffi-
ciency only in 54 (29%), and stenosis only in 16 (9%)
patients. Valves used included aortic homograft in 74
(39%), pulmonary autograft (as a complete root replace-
ment) in 68 (36%), mechanical valves in 36 (19%)
(St Jude Medical 21, St Jude Medical with composite root
15 [St Jude Medical, Inc, St Paul, Minn]), and bioprosthetic
valves in 10 (6%) (Medtronic Freestyle 6 [Medtronic, Inc,
St Paul, Minn], St Jude Medical Epic 3, St Jude Medical Bi-
ocor 1). An aortic root–enlarging (Konno or Manougian)
procedure was concomitantly performed in 27 (14%) pa-
tients (16 with the Ross procedure, 9 with homografts, 2
with mechanical valve replacements) (Table 3).
Postoperative Course
Hospital complications included arrhythmias requiring
treatment in 5 (3%) (2 complete atrioventricular block, 2
supraventricular tachycardia, 1 atrial ectopic tachycardia),
bleeding requiring reexploration in 3 (2%), and stroke,
deep vein thrombosis, and vocal cord paralysis in 1 each
(<1%). There were 6 hospital deaths, 4 in patients who
received a homograft AoVand 2 in patients who underwent
a Ross procedure. The 4 deaths in homograft recipients
included 3 in infants (2 Shone complex, 1 interrupted aortic
arch) and 1 in a neonate (Shone complex). Two of these
patients had pulmonary hypertension, and 2 were hemody-
namically unstable requiring support with an extracorporeal
membrane oxygenator. The 2 autograft recipients who died
included an infant and a neonate both with a diagnosis
of Shone complex. Causes included pulmonary hyperten-
sion and hemodynamic instability requiring support with
an extracorporeal membrane oxygenator. The overallThe Journal of Thoracic and Cahospital survival of patients undergoing AoV replacement
was 97%.
Late Complications
Themean duration of follow-up for the valve replacement
cohort was 5.0 4.0 years (0 days-15 years) (Table 2). Com-
plications according to valve types were as follows:
Homograft valves. Seventy-four homografts were im-
planted in 65 patients. At a mean follow-up of 4.0  4.0
years (0 days-13.6 years) there were 27 (36%) reoperations
and 5 late deaths. At reoperation, 12 of the 27 received a pul-
monary autograft, 8 had a homograft of a larger size, and 7
had a mechanical valve. Complications in patients who
were alive without reoperation at follow-up included left
ventricular dysfunction requiring an implantable defibrilla-
tor in 1 (2%), ventricular tachycardia requiring a pacemaker
in 1 (2%), and syncope in 1 (2%). Medications at last
follow-up included aspirin in 23 (55%), beta-blockers in 8
(19%), angiotensin-converting enzyme inhibitor/angioten-
sin receptor blocker (ACEi/ARBS) in 4 (9%), furosemide
in 3 (7%), calcium-channel blockers in 2 (5%), and couma-
din, digoxin, enoxaparin, and dipyridamole in 1 each (2%).
Autograft valves. Of the 68 patients undergoing a Ross
procedure, 3 (4%) had a reoperation on the neo-AoV (2 me-
chanical valves, 1 valve-sparing root repair). There were
2 late deaths during a mean follow-up of 6.7  4.2 years
(4 days-15 years). Of the patients who were alive without
further AoV reintervention, 16 (26%) had right-sided con-
duit reintervention, 1 (2%) stroke secondary to antiphos-
pholipid antibody syndrome, and 1 (2%) had a pacemaker
for heart block. Medications at last follow-up included aspi-
rin in 29 (47%), ACEi/ARBS in 18 (29%), beta-blockers in
14 (23%), coumadin and digoxin in 2 (3%) each, and furo-
semide and thiazide diuretic in 1 (2%) each.rdiovascular Surgery c Volume 146, Number 3 515
FIGURE 1. FRD for simple and complex AoV repairs (A), for all AoV repairs according to diagnostic group (B), and for all AoV repairs according to age
group (C). FRD, Freedom from reintervention or death; AoV (AV), aortic valve; CHD, congenital heart disease; Ds, disease.
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valves implanted in 36 patients. At a mean follow-up of 4.6
 3.3 years (9 days-13.3 years), there was 1 (3%) reopera-
tion with an autograft and 1 (3%) late death. The complica-
tions noted at the last follow-up were valve thrombus in
1 (3%), atrial ectopic tachycardia in 1 (3%), stroke in 1
(3%), and syncope in 1 (3%). Medications at last follow-
up included coumadin in 30 (88%), beta-blockers in 9
(26%), ACEi and digoxin in 7 (21%) each, aspirin and fu-
rosemide in 6 (18%) each, and dipyridamole in 4 (12%).
Bioprosthetic valves. Of the 10 patients who had a bio-
prosthetic valve implanted, none had a reoperation and no
deaths were reported. The follow-up was complete for these
patients with a mean follow-up of 3.0  1.2 years (7
months-4.4 years). Complication was reported in 1 patient
(severe valve insufficiency after an episode of endocarditis)
awaiting reoperation. Medication at last follow-up in-
cluded, aspirin in 4 (40%) and beta-blockers in 3 (30%).Children With Multiple Valve Replacements
Of the children in the AoV replacement cohort, 23 had
a second valve replacement at age 18 years after a mean
follow-up time of 3.2  2.4 years. Twenty-two of the 23
children had a homograft root as the primary valve replace-
ment and 1 had a Ross procedure. The second valve option516 The Journal of Thoracic and Cardiovascular Surgat reoperation for the 22 homograft valve replacement fail-
ures were the Ross procedure in 10 patients, a second homo-
graft in 9 patients, and a mechanical valve in 3 patients. Of
the 9 patients who had a second homograft root replace-
ment, 3 required a third valve replacement (2 had a Ross
procedure, 1 had a mechanical valve) at age 18 years.
Therewas 1 death at long-term follow-up reported in the pa-
tients who had multiple valve replacements in childhood
and that in a patient who had an autograft primary valve re-
placement followed by a mechanical valve.Risk Factors for Replacement Failures and FRD
On univariate analysis, replacement failures (reoperation
or death) were significantly more frequent in infants
(P<.0001), in patients without a history of surgical or per-
cutaneous valve interventions (P ¼ .003), and in those with
concomitant CHD (P<.0001). Replacement failures were
associated with homograft valve replacements (P<.0001).
Multivariable Cox regression analysis of these factors
showed that infants (hazard ratio, 9.1; P<.0001) and indi-
viduals undergoing a homograft valve replacement (hazard
ratio, 15.5; P<.0001) were more likely to have a valve re-
placement failure. On Kaplan-Meier analysis, homograft
valve replacements were associated with a lower FRD
than all other types of valve replacements (P .05). Infantsery c September 2013
FIGURE 2. FRD for different types of AoV replacements (A), for all AoV replacements according to diagnostic group (B), and for all AoV replacements
according to age group (C). FRD, Freedom from reintervention or death; AoV (AV), aortic valve; CHD, congenital heart disease; Ds, disease.
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patients with concomitant CHD had significantly lower
FRD than those with dysfunction of AoVonly (P<.0001)
(Figure 2, A-C).
DISCUSSION
This study underscores the diversity of the population of
children with AoV disease requiring surgical intervention.
Although acceptable outcomes have been achieved using
a wide variety of surgical options, no single approach offers
immunity from the potential for reoperation or long-term
complication.
As in other pediatric centers, our institutional preference
has been to repair the nativeAoVwhenever possible. This op-
tion appears to benefit the patient by minimizing the need for
anticoagulation, preserving the potential for somatic growth,
and preserving the opportunity to use other replacement op-
tions in the future. In our experience, reoperation for early
or late failure of a repaired AoV has been associated with
low risk of mortality (5%). These results are consistent
with published AoV repair series in pediatric patients.4,9,10
The rate of reoperation is also similar to previous study,
with recurrence of dysfunction after repair being primarily
dependent on the valvular structure.11 We classified major
AoV reconstructions including truncal valve repairs andThe Journal of Thoracic and Cavalve-sparing root repairs in the complex AoV repair cate-
gory. It is encouraging that outcomes for this group were
not demonstrably different from the simple repair group.
For an algorithmofdecisionmaking in children requiring aor-
tic valve surgery, refer to Figure 3.
AoV replacement in this study was associated with excel-
lent survival and low morbidity. Overall, valve replacement
outcomes of our patients were comparable with published
pediatric literature.12,13 Patients more likely to have failure
of replacement included the patients that had other signifi-
cant CHD. This group included a variety of diagnoses
with patients frequently undergoing multiple concomitant
intracardiac repairs along with AoV replacement. Interest-
ingly, patients undergoing truncal valve replacement were
found to have a superior FRD rate to others in CHD group.
This is in contradistinction to published series of truncal
valve repairs and replacements in which long-term survivals
have been noted to be compromised.14
Of the valve replacement options applied to small patients
(children in whom adult-sized prostheses cannot be used),
the Ross procedure appears to be the most durable.15,16
Although not always possible owing to anatomic defects
and clearly a more technically demanding procedure,
several large studies including our own have shown
excellent midterm and long-term results.17-20 Our currentrdiovascular Surgery c Volume 146, Number 3 517
FIGURE 3. Algorithm at Texas Children’s Hospital for aortic valve surgery for newborns/infants (A), school age to adolescent-sized children (B),
and adolescents and adult-sized children (C).
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of reoperation and death. We have adopted a selective
approach to the Ross procedure in smaller patients and
have often ‘‘staged’’ smaller children with an intervening
homograft before the index Ross procedure with good
results. Reoperation for the right-sided valved conduit re-
mains an important concern for this group of patients.518 The Journal of Thoracic and Cardiovascular SurgAortic homograft valves were frequently implanted in
this series. This option has been favored for some of our
smaller patients and in patients whose anatomy precludes
a Ross procedure. A recent randomized controlled trial in
adults demonstrated improved survival, freedom from reop-
eration, and quality of life for autograft versus the homo-
graft root replacement.21 These data along with our ownery c September 2013
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tion of the Ross procedure in childhood may be justifiable.
Mechanical valves may be considered a durable option
for the treatment of AoV disease in children.20 Limitations
in the pediatric population are magnified in the very young
and include somatic outgrowth and the challenges of
managing anticoagulation. We observed 100% short-term
survival and 2 failures at long-term follow-up. Of the
5 patients less than 5 years of age at time of mechanical
AoV replacement in our series, all are doing well at
follow-up on anticoagulation. Fifty percent of our patients
had CHD and 50% of the patients had undergone a previous
surgical or catheter AoV intervention. Both factors appear
to have no impact on outcomes as described by others.22,23
Our results with the use of mechanical valves confirm that
this valve can be reliably used in the pediatric population
if anticoagulation can be appropriately managed. In our
cohort, 9% of patients who were on anticoagulation had
a complication at long-term follow-up.
There are very limited data concerning the application of
bioprosthetic valves in the pediatric population, with most
studies focused on the use of this option in late teenage
years.24,25 Previous studies have implied that use of
bioprosthetic valves in pediatric years is a risk factor for
valve failure.12,25 Our experience, although quite limited,
suggests the newer generations of bioprostheses may be
more durable, particularly when larger sizes can be used
to obviate the needs of somatic growth. At present follow-
up, there have been no reoperations or mortality in our se-
ries, although 1 patient has evidence of valve deterioration
(after endocarditis) and will require reoperation. The small-
est patient in our series was a 5-year-old who received
a complete porcine root (Medtronic Freestyle). Overall,
our experience with the use of bioprosthetic valves is en-
couraging and we promote the application of this option
in older children.
The current study confirms that infants undergoing AoV
repair or a replacement represent a higher risk group. These
data are consistent with findings as reported by Karamlou
and associates,12 in which both low age and weight were re-
ported to be associated with replacement failure. With 69
infant operations including 34 replacements (19 homografts
and 15 Ross procedures), we report the largest series of
infants from a single institution. Despite improvements in
management for this high-risk group compared with the
older children, there is still room for progress. It is notewor-
thy that the majority of smaller patients have severe, life-
threatening disease that puts them at a higher risk for
morbidity and mortality. In our replacement cohort, all of
the early deaths were in infants.
Study limitations include the inherent limitations of
a retrospective design. Patients included had diverse anat-
omy and underwent a variety of treatments during the
follow-up period. Indications and timing of surgery andThe Journal of Thoracic and Cathe operative technique may also have varied over the study
period. Details of the right-sided conduit for the Ross pro-
cedure concomitantly performed were not collected for
this study. Management of patients after operation has
also changed considerably over the 16-year period of this
study, the effect of which was not separately evaluated.
Last, a comprehensive set of variables were collected to
study the different surgical options; however, the unmea-
sured covariates may have also affected the results. None-
theless, this study represents the reality of practice in
a large, quaternary children’s hospital and emphasizes the
imperfect nature of all treatment options for children with
AoV disease.
In conclusion, AoV repair and replacement are satisfac-
tory surgical options associated with acceptable overall sur-
vival and low morbidity. Surgical strategy should include
not only the limitations and risks of all options, but increas-
ingly, the informed opinion of the family. Complex and sim-
ple repairs have similarly good long-term outcomes. The
Ross procedure, as well as use of mechanical and biopros-
thetic valves, is associated with excellent results whereas
right-sided intervention with the Ross procedure remains
a concern. Although aortic homografts should remain part of
the treatment armamentarium, caution concerning long-
term durability should be exercised in selecting this option.
Without doubt, there is much room for improvement in the
development of more idealized valve substitute options for
children.
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Dr Tara Karamlou (San Francisco, Calif). Thank you, Dr
Khan. Dr Khan and colleagues are to be commended for tackling
the problem of determining the ‘‘ideal’’ AoV intervention for AoV
disease in pediatric patients. The study was well conceived and ex-
ecuted, represents one of the largest series of infants undergoing
intervention, and Dr Khan provided the manuscript to me well in
advance of the meeting. The 98% survival is commendable and
the 85% follow-up of the cohort, which included outreach to pa-
tients not followed up at their institution, is also excellent. The
study is a retrospective review of 285 AoV repairs and replace-
ments in 241 patients over a 16-year period. The authors report
that for valve repair, infants and those with truncus arteriosus
had higher risk for the primary composite end point of death and
reoperation. Similarly, risk factors for the composite end point
for valve replacement cases included infants, those with concom-
itant CHD, and those having homograft valves.520 The Journal of Thoracic and Cardiovascular SurgThe good points regarding the study notwithstanding, the results
elucidated are not novel inasmuch as several prior publications
have shown that patients of younger age, those receiving homo-
graft valves, and those with concomitant CHD including truncus
arteriosus to have worse outcomes than other pediatric patients un-
dergoing AoV intervention.
With this in mind, I have several questions for the authors.
The authors stated in their conclusions, and some of these are
conclusions from the manuscript and not necessarily from the pre-
sentation, that patients having homograft valve replacements have
lower freedom from their composite end point of reoperation and
death. Patients having homografts, however, were significantly
younger and had significantly smaller valves implanted, often 15
mm versus 22 mm for the other valve types, compared with other
replacement patients. Furthermore, the authors stated that they had
adopted a policy to ‘‘stage’’ smaller children with an intervening
homograft valve before performing an index Ross operation. In
other words, replacing the homograft was really a fait accompli.
Finally, since era was not mentioned as a covariate, and consider-
ing the fact that the study circumscribed a broad historical period,
was the policy of staging patients adopted on the basis of a prior
analysis of patients undergoing the Ross operation from your
own institution?
In other words, my question is, based on these confounders, do
the authors believe that their study may be unfairly biased against
homograft valves?
Dr Khan. Thank you, Dr Karamlou, for your thoughtful com-
ments. We agree with your observation that much of what we pres-
ent in this paper is not novel; however, many of those data you refer
to represent aggregatemulti-institutional series andwe believe that
it is important for individual institutions to carefully monitor their
own experience as this is the end point between the patient and the
heart team.
Regarding the questions, we purposely elected to study a time
frame representative of a consistent management strategy and
team. Although multiple surgeons were involved, the approach
to smaller patients, particularly those in whom there is a very
large size discrepancy between the pulmonary valve and native
or reconstructed aortic root, has remained constant. Our thinking
has been that using a small homograft as a primary reconstructive
method with the expectation, as you correctly note, of an early
reoperation on the root allows a more durable application of
the Ross procedure. This has been borne out in our experience
with a low risk of subsequent Ross procedure after primary ho-
mograft root replacement. That being said, given our current
data analysis, we are likely to adopt at our institution a somewhat
more liberal application of the Ross procedure in smaller
children.
Dr Karamlou. I was confused by the statement made in the
manuscript that complex valve repairs fared no worse than simple
valve repairs. First, the complex repair group included all of the
truncal valve interventions, which were identified as a risk factor
for reoperation and death, and the Kaplan-Meier plot showed
a 5-year freedom from your composite end point of 84% for simple
repairs compared with a 5-year freedom of 61% for complex re-
pairs. Although the P value reported is .07, the curves are impres-
sively different. Considering the difference in follow-up favoring
the simple group, do the authors really believe that there is noery c September 2013
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Dclinically important difference among these groups? In other
words, is this really a type 2 error?
Dr Khan.We agree that this might be actually clinically signif-
icant difference, but statistically it was not significant. That is what
we reported, and we made a slight change in the final manuscript.
Dr Karamlou. Can the authors elaborate on their institutional
approach to patients with truncal valve dysfunction? Considering
the considerably worse outcomes in this group, at what age and
at what level of dysfunction do they recommend intervening on
the valve?
Dr Khan. Regarding our approach to truncal valves, we have
chosen to be aggressive with repair even at that time of the primary
operation. As you know, acute significant truncal insufficiency is
an important risk factor for patients undergoing truncus repair.
As such, we have liberally approached various truncal valve repair
methods including rudimentary sinus resection, leaflet suspension
and extension, and bicuspidization. For irreparable truncal valves,
we agree that mechanical valve replacement is a useful option but
have elected to defer this option in most cases until a suitably large
valve can be placed to limit the potential of somatic outgrowth. We
also favor minimizing the obligate challenges associated with
managing warfarin in children.
Dr Ross Ungerleider (Winston-Salem, NC). Very nice. It is
a wonderful series. I am sitting here trying towrapmy brain around
it and so I hope my questions are not na€ıve.
First of all, you started out your presentation with this case his-
tory of a woman with multiple reinterventions but not death. I am
puzzled why you would combine freedom from death or reinter-
vention in your graphs because they are very different outcomes.
As you go about revising this manuscript, you might find it useful
to separate those two things out because death is such a different
outcome. It may be the eventual outcome of multiple reinterven-
tions. Can you comment about why you chose to put those two to-
gether? I think they might obscure some of the conclusions that
you are trying to make.
DrKhan. Thank you for your question. The primary reason that
we chose to include death and reintervention together is that we
were trying to show the worst case scenario from a valve replace-
ment. The most difficult question to answer is when a parent asks,
‘‘How long will the valve survive?’’ We wanted to present the
whole picture to parents.
Dr Ungerleider. Another question is that your incidence
of right ventricle–pulmonary artery conduit replacement in theThe Journal of Thoracic and Capatients with autografts was high at 26%. Could you comment
on that? Do you think that some of that was related to patients out-
growing their conduit or did you have a conduit deterioration rate
that was about a quarter of the patients? I am curious what conduit
you are using in those cases.
Dr Khan. I would ask Dr Fraser to comment on the type of con-
duit that we use.
Dr Fraser.Dr Ungerleider, thanks for your comments. We used
almost exclusively homografts, but I think we are fairly aggressive
about reintervening on the right ventricle–pulmonary artery con-
duit. As you know, the Contegra conduit (Medtronics) is not
even approved for use in this indication, sowe inserted only 2 Con-
tegra homografts in this series, but we have a relatively aggressive
institutional stance to conduit replacement. In our experience, ho-
mografts in the current era are not particularly predictable.
Dr Ungerleider. I think there are a lot of conduits out there that
are not being replaced but are dysfunctional. In the past year, we
have been making polytetrafluoroethylene (W.L. Gore & Associ-
ates, Inc, Flagstaff, Ariz) valves. We have altered the technique
that Jim Quintessenza has described and are making trileaflet
valves. Jim has been making bileaflet polytetrafluoroethylene
valves. We are placing these valves in a tube, similar to our mod-
ified Ross procedure. We think these may be better than allografts.
I do not know, but it just was an interesting number. It caught my
attention.
Finally, why did you include the truncus patients in this? I know
they are getting AoV replacements. However, because some op-
tions are not available to them, they may also tend to obscure
and contaminate the data unless they are looked at as a separate
group. They cannot get autografts, for example. I am just curious
about the thinking of including them.
Dr Fraser. As Dr Khan noted, our goal was to present the
worst case scenario for aortic root interventions in our hospital.
Notwithstanding the fact that there are multiple other previous
series published, we thought that having a snapshot of what we
have been doing in our hospital and particularly in the context
of counseling families at the time of this difficult decision is im-
portant. I find the AoV consults with families one of the most
difficult and lengthy consults I have with patients before surgery.
Trying to provide them the profile of all-comers and what our
experience has been seemed important. Admittedly, the truncus
patients are the worst actors in terms of truncal/AoV durability
and risk profile.rdiovascular Surgery c Volume 146, Number 3 521
